ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

最近更新时间: 4天之前, 3:24AM

228.20

3.06 (1.36%)

  • 1天 1.36%
  • 5天 -0.02%
  • 1月 -0.86%
  • 6月 16.39%
  • 今年至今天 27.17%
  • 1年 13.83%
  • 5年 141.48%
前收盘价格 225.14
收盘价格 227.05
成交量 4,984,511
平均成交量 (3个月) 5,294,409
市值 403,128,582,144
市盈率 (P/E TTM) 108.67
预期市盈率 (P/E Forward) 16.84
价格/销量 (P/S) 7.19
股市价格/股市净资产 (P/B) 50.46
52周波幅
163.81 (-28%) — 244.81 (7%)
利润日期 31 Oct 2025
股息率 (DY TTM) 2.12%
营业毛利率 7.31%
营业利益率 (TTM) 30.43%
稀释每股收益 (EPS TTM) 2.35
季度收入增长率 (YOY) 8.40%
季度盈利增长率 (YOY) -6.10%
总债务/股东权益 (D/E MRQ) 4,789.60%
流动比率 (MRQ) 0.760
营业现金流 (OCF TTM) 16.40 B
杠杆自由现金流 (LFCF TTM) 16.94 B
资产报酬率 (ROA TTM) 8.34%
股东权益报酬率 (ROE TTM) 88.40%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看跌
Drug Manufacturers - General (全球的) 看涨 看跌
股票 AbbVie Inc. 看涨 看涨

AIStockmoo 评分

-0.5
分析师共识 1.5
内部交易活动 NA
价格波动 -0.5
技术平均移动指标 -2.5
技术振荡指标 -0.5
平均 -0.50

相关股票

股票 市值 DY P/E（TTM） P/B
ABBV 403 B 2.12% 108.67 50.46
JNJ 450 B 1.33% 18.04 5.71
PFE 138 B 3.51% 12.83 1.58
GSK 95 B 0.83% 13.39 4.42
BMY 92 B 1.37% 18.13 5.34
LLY 787 B 0.32% 43.02 40.22

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.10%
机构持股比例 74.87%
52周波幅
163.81 (-28%) — 244.81 (7%)
目标价格波幅
222.00 (-2%) — 284.00 (24%)
高 284.00 (Piper Sandler, 24.45%) 购买
中 250.00 (9.55%)
低 222.00 (Evercore ISI Group, -2.72%) 购买
平均值 250.82 (9.91%)
总计 9 购买, 2 保留
平均价格@调整类型 225.47
公司 日期 目标价格 调整类型 价格@调整类型
Citigroup 03 Nov 2025 235.00 (2.98%) 保留 228.20
JP Morgan 03 Nov 2025 260.00 (13.94%) 购买 228.20
16 Sep 2025 235.00 (2.98%) 购买 216.26
Guggenheim 20 Oct 2025 242.00 (6.05%) 购买 232.06
Raymond James 17 Oct 2025 250.00 (9.55%) 购买 229.57
Piper Sandler 10 Oct 2025 284.00 (24.45%) 购买 230.50
12 Aug 2025 231.00 (1.23%) 购买 198.64
B of A Securities 03 Oct 2025 251.00 (9.99%) 保留 233.91
Evercore ISI Group 22 Sep 2025 222.00 (-2.72%) 购买 222.59
Berenberg 17 Sep 2025 270.00 (18.32%) 购买 220.81
Cantor Fitzgerald 15 Sep 2025 245.00 (7.36%) 购买 217.61
BMO Capital 12 Sep 2025 240.00 (5.17%) 购买 218.34
Wells Fargo 12 Sep 2025 260.00 (13.94%) 购买 218.34
显示更多

该时间范围内无数据。

  • 3M
日期 类型 细节
29 Oct 2025 公告 The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
29 Oct 2025 公告 AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
28 Oct 2025 公告 Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
21 Oct 2025 公告 The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
20 Oct 2025 公告 RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
17 Oct 2025 公告 AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
13 Oct 2025 公告 U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
13 Oct 2025 公告 AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
09 Oct 2025 公告 SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
06 Oct 2025 公告 AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
02 Oct 2025 公告 AbbVie to Host Third-Quarter 2025 Earnings Conference Call
01 Oct 2025 公告 Natrelle® Awarded Supplier Agreement from Vizient
30 Sep 2025 公告 AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
30 Sep 2025 公告 AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
29 Sep 2025 公告 AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
29 Sep 2025 公告 AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
26 Sep 2025 公告 AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
25 Sep 2025 公告 Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
23 Sep 2025 公告 Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
09 Sep 2025 公告 BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
05 Sep 2025 公告 AbbVie Declares Quarterly Dividend
03 Sep 2025 公告 AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
03 Sep 2025 公告 Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
02 Sep 2025 公告 AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
25 Aug 2025 公告 AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
21 Aug 2025 公告 AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
19 Aug 2025 公告 AbbVie Completes Acquisition of Capstan Therapeutics
19 Aug 2025 公告 SkinMedica® Unveils Its Newest Hydration Hero
12 Aug 2025 公告 AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
06 Aug 2025 公告 Get Ready, JUVÉDERM® Day is Calling!
05 Aug 2025 公告 Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
显示更多
股息率 (DY TTM) 2.12%
5年平均股息收益率 3.81%
股息支付比率 268.80%
预计下次股息支付 Feb 2026
除息日 公告日期 支付日期 详情
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 现金
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 现金
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 现金
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 现金
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 现金
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 现金
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 现金
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 现金
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 现金
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 现金
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 现金
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 现金
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 现金
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 现金
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 现金
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 现金
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 现金
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 现金
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 现金
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 现金
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 现金
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 现金
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 现金
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 现金
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 现金
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 现金
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 现金
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 现金
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 现金
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 现金
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 现金
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 现金
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 现金
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 现金
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 现金
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 现金
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 现金
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 现金
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 现金
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 现金
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 现金
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 现金
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 现金
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 现金
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 现金
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 现金
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 现金
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 现金
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 现金
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票